Lupin and Galenicum Strategic Alliance: Expanding Injectable Semaglutide Access Globally

In a major move to capture the booming global metabolic health market, Lupin Limited has announced a multi-market licensing and supply agreement with Spain’s Galenicum Health, S.L.U. The partnership focuses on the commercialization of injectable Semaglutide, the high-demand GLP-1 receptor agonist used for treating Type 2 diabetes and chronic weight management.

The deal, managed via Lupin’s subsidiary Lupin Atlantis Holdings SA (LAHSA), grants Lupin exclusive rights to commercialize and distribute the therapy across 23 global markets, including:

North America: Canada
Europe: Multiple key nations
Latin America: Diverse emerging markets
Southeast Asia: High-growth regions

Strategic Division of Labor

The alliance leverages the specific core competencies of both pharmaceutical entities:

Galenicum Health: Responsible for the technical development, manufacturing, and long-term supply of the finished injectable formulations.
Lupin Limited: Will spearhead all regulatory filings, secure necessary local approvals, and lead the commercial rollout using its established distribution infrastructure.

Riding the GLP-1 Wave

The partnership comes at a time when the global Semaglutide market is seeing unprecedented growth. According to industry reports from January 2026:

The global Semaglutide market was valued at approximately $27.79 billion in 2025.
It is projected to reach $59.75 billion by 2033, growing at a CAGR of 10.04%.
The Asia-Pacific region is expected to be the fastest-growing market, with a projected CAGR of 11.71% due to rising urbanization and lifestyle changes.

Impact on Global Health

With diabetes prevalence escalating—affecting over 11% of the global adult population in certain regions—and obesity being recognized as a critical health priority, Semaglutide has become a “cornerstone” therapy.

“Our partnership with Galenicum is a strategic milestone… with our extensive presence across Europe, Canada, and SE Asia, we are positioned to scale access to high-quality, cost-effective treatment options at the right moment.” — Fabrice Egros, President – Corporate Development, Lupin.

Corporate Profiles

Lupin Limited: Headquartered in Mumbai, Lupin is a top-tier global player with 15 manufacturing sites and a presence in 100+ markets. It is a leader in cardiovascular, anti-diabetic, and respiratory therapy areas.
Galenicum Health: Based in Barcelona, Galenicum specializes in value-added generics and B2B pharmaceutical solutions, with a significant R&D focus on the GLP-1 pipeline.